Mushroom Supplements: Lion's Mane, Reishi, and What Works

Medicinal mushrooms are everywhere now — lion's mane, reishi, chaga, cordyceps, and turkey tail show up in coffee blends, gummies, and expensive multi-mushroom powders. Each species has a different mix of bioactive compounds and a different evidence base. Marketing treats them as interchangeable wellness products. The clinical research does not.

Lion's Mane: The Strongest Cognitive Evidence

Lion's mane (Hericium erinaceus) contains hericenones and erinacines, compounds that increase nerve growth factor (NGF) in laboratory and animal studies. The clinical evidence in humans is small but consistent in older adults with mild cognitive impairment (MCI). A 16-week double-blind RCT in 50 Japanese adults with MCI (Mori 2009 PMID 18844328) gave 3 g/day of lion's mane or placebo and reported higher cognitive-function scores in the supplement group, with the benefit fading after the supplement was stopped. A 2019 RCT in 31 older Japanese adults reported improvements in cognitive function on the MMSE-J after 12 weeks of erinacine A–enriched lion's mane (Saitsu 2019 PMID 31553601). Healthy-young-adult evidence is much thinner. Quality matters: products made from mycelium grown on grain substrate are mostly grain starch with little of the active compounds; look for fruiting-body extracts with beta-glucan content above 25% and disclosed alpha-glucan (starch) below 5%.

Reishi: Sleep and Immune Modulation

Reishi (Ganoderma lucidum) has older clinical work on neurasthenia — a 2005 RCT in 132 patients found a polysaccharide extract reduced fatigue and improved well-being (Tang 2005 PMID 15857210). Sleep-quality data is weaker than commonly stated; most positive trials are small or use proprietary extracts. The polysaccharide fraction modulates innate immunity in laboratory and animal models, and reishi is sometimes used as an adjunct in oncology supportive care — a 2016 Cochrane review (Jin 2016 PMID 27045603) found very low–quality evidence that Ganoderma may augment chemotherapy response and modestly improve quality of life, but cautioned against using it as a primary cancer treatment.

Cordyceps and Chaga

Cordyceps is marketed for athletic performance. A small RCT in trained adults (Hirsch 2017 PMID 28316263) reported modest improvements in tolerance to high-intensity exercise after chronic Cordyceps militaris supplementation; effects on VO₂max have been small and inconsistent across trials. Chaga (Inonotus obliquus) has extensive in vitro and animal data but essentially no controlled human trials. Marketing is well ahead of evidence. Chaga also contains high levels of oxalates — case reports of oxalate-related acute kidney injury have been published in patients who consumed chaga at gram-scale daily doses (Kikuchi 2014 PMID 24558428), so people prone to kidney stones or with chronic kidney disease should avoid it.